Profusa Drops 12% Management Equity Grant from $30M PanOmics Acquisition
PFSA is trading near its 52-week low of $0.361 (2.4% above the low).
Summary
Profusa amended its $30 million asset purchase agreement for the PanOmics Assay, eliminating a provision that would have granted management 12% of the fully diluted common stock. This follows the definitive agreement for the PanOmics acquisition announced on April 27th, which was already structured with highly dilutive convertible preferred stock. Given Profusa's ongoing financial distress, delisting threats, and recent filings for massive share dilution, removing this significant management equity grant is a positive development for existing shareholders, reducing the overall dilutive impact of the acquisition.
At the time of this announcement, PFSA was trading at $0.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7M. The 52-week trading range was $0.36 to $975.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.